[1] XU Haiyan ZHANG Linlin LIN Jie JIA Wei,.Effect of Guifei Liqi Prescription on The Treatment of Phlegm Heat Type in Acute Exacerbation of Chronic Obstructive Pulmonary Disease [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2021, (04): 105-109. [doi: 10.13424/j.cnki.jsctcm.2021.04.024]
Effect of Guifei Liqi Prescription on The Treatment of Phlegm Heat Type in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Article number:
- 2096-1340(2021)04-0105-05
- Keywords:
- Guifei Liqi formula; Chronic obstructive pulmonary disease; Phlegm heat obstructing lung syndrome; Serum inflammatory markers; Pulmonary function
- ZTFLH:
- R563.3
- Code:
- A
- Abstract:
- Objective To explore the clinical effect of Guifei Liqi Decoction on acute exacerbation of chronic obstructive pulmonary disease.Methods 60 patients with acute exacerbation of chronic obstructive pulmonary disease with phlegm heat obstructing lung syndrome were randomly divided into control group and treatment group.The control group was treated with conventional western medicine，while the treatment group was treated with Guifei Liqi Decoction on the basis of conventional western medicine.Results After treatment，the total effective rate of the treatment group (96.7%) was higher than that of the control group (86.7%，P<0.05); After treatment，WBC，CRP and IL 6 were improved in both groups; The indexes of the treatment group were better than those of the control group (P<0.05).Conclusion Guifei Liqi decoction combined with conventional western medicine can effectively reduce WBC，CRP and IL 6 serum inflammatory indexes，improve lung function，relieve the clinical symptoms of patients with acute exacerbation of chronic obstructive pulmonary disease with phlegm heat obstructing lung syndrome，and improve the curative effect.
References:
［1］Bellou V,Belbasis L,Konstantinidis AK,et al.Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease:systematic review and critical appraisal［J］.BMJ,2019,367:1-15.
［2］Stolz D,Kostikas K,Loefroth E,et al.Differences in COPD Exacerbation Risk Between Women and Men:Analysis From the UK Clinical Practice Research Datalink Data［J］.Chest,2019,156(4):674-684.
［3］Wang N,Cong S,Fan J,et al.Geographical Disparity and Associated Factors of COPD Prevalence in China:A Spatial Analysis of National CrossSectional Study［J］.International journal of chronic obstructive pulmonary disease,2020,15:367-377.
［4］刘英超.苏子降气汤辅助治疗COPD急性发作期的临床研究［J］.继续医学教育,2020,34(1):151-153.
［5］纪弦弦,陈曦,朱文明.越婢加半夏汤对老年急性加重期慢性阻塞性肺病的疗效及机制探讨［J］.当代医学,2020,26(7):137-139.
［6］柯学,彭俊杰,欧形.清热通瘀方对COPD急性加重期的疗效观察［J］.中医临床研究,2018,10(20):34-35.
［7］中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医证候诊断标准(2011版)［J］.中医杂志,2012,53(2):177-178.
［8］蔡柏蔷,陈荣昌.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)［J］.国际呼吸杂志,2017,37（14）:1041-1057.
［9］林涛.加味越婢汤对慢性阻塞性肺疾病急性加重期患者免疫功能及气道重塑的影响［J］.湖南中医杂志,2020,36(7):38-40.
［10］李锋,周新.慢性阻塞性肺疾病的发病机制研究进展［J］.中国呼吸与危重监护杂志,2019,18(1):88-92.
［11］管频,李伟.慢性阻塞性肺疾病气道炎症与气道重塑研究进展［J］海南医学.2010,21(17):114-116.
［12］吴林,尹文.慢性阻塞性肺疾病急性加重的诊疗进展［J］.中国急救医学,2019,39(5):486-490.
［13］KanohS,Rubin BK.Mechanisms of action and clinical application of macrolides as immunomodulatory medications［J］.ClinMicrobiolＲev,2010,23(3):590-615.
［14］邓虎,徐艳玲.补肾中药复方对慢性阻塞性肺疾病患者疗效观察［J］.中华中医药学刊,2016,34(4):915-917.
［15］刘建立,逯世林.PCT、CRP和WBC测定对临床感染性疾病的诊断价值［J］.临床医药实践,2015,24(11):834-835.
［16］Colten DB,Berbari MD,Arlen DH,et al.Systemic inflammatory markers and aspiration cell count may not differentiate bacterial from fungal prosthetic infections［J］.Clin Orthop Relat Res,2014,472(11):3291-3294.
［17］黄楚燕,梁宏宇.自拟加味瓜蒌薤白半夏汤对痰热蕴肺型慢性阻塞性肺疾病急性加重期患者炎症因子及凝血功能的影响［J］.广州中医药大学学报,2019,36(2):181-185.
［18］路东明,宗晓福,张文娟.血清炎症因子与慢阻肺急性加重期肺功能的相关性［J］.临床肺科杂志,2015,20(11):2067.
Memo
基金项目：上海市卫生和计划生育委员会（201640098）；上海市虹口区卫生和计划生育委员会（HGY-YSZK-2018-14）